Narcolepsy Pipeline Summary

DelveInsight’s, “Narcolepsy - Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Narcolepsy: Understanding

Narcolepsy: Overview

Narcolepsy is a chronic neurological sleep–wake disorder characterized primarily by excessive daytime sleepiness (EDS) and an inability to maintain stable wakefulness. It is generally classified into narcolepsy type 1 (NT1), typically associated with cataplexy and orexin/hypocretin deficiency, and type 2 (NT2), which generally lacks cataplexy and has preserved orexin levels. The disorder can substantially impair attention, memory, academic or occupational performance, social functioning and quality of life. Although relatively uncommon, narcolepsy is frequently underrecognized and diagnosis can be delayed for several years.

The hallmark symptom is persistent excessive daytime sleepiness, often accompanied by irresistible sleep episodes or “sleep attacks” despite adequate nighttime sleep. NT1 is characterized by cataplexy, a sudden, brief loss of muscle tone triggered by emotions such as laughter, excitement or anger while consciousness is retained. Other manifestations include sleep paralysis, hypnagogic or hypnopompic hallucinations, fragmented nighttime sleep and automatic behaviors. Patients may also experience impaired concentration and memory, mood disturbances and other sleep-related problems.

The underlying cause of narcolepsy is not completely established, but NT1 is strongly associated with selective loss of orexin/hypocretin-producing neurons in the lateral hypothalamus, which normally help stabilize wakefulness and suppress inappropriate REM-sleep features during wakefulness. Evidence suggests that this neuronal loss is probably mediated by an autoimmune process in genetically susceptible individuals, with a strong association with HLA-DQB1*06:02. Environmental factors, including infections and other immune triggers, may contribute to disease onset. Loss of orexin signaling destabilizes the normal boundaries between wakefulness, non-REM sleep and REM sleep, producing the characteristic combination of EDS, cataplexy and REM-related symptoms.

Diagnosis is based on clinical history together with objective sleep testing, primarily overnight polysomnography followed by a multiple sleep latency test (MSLT) to document pathological sleepiness and sleep-onset REM periods. CSF orexin/hypocretin-1 measurement can support NT1 diagnosis, particularly when cataplexy is absent or the presentation is atypical, while HLA testing may provide supportive evidence but is not diagnostic on its own. There is currently no established cure, so treatment focuses on controlling EDS, cataplexy and other symptoms through wake-promoting agents, stimulants and anticataplectic therapies such as sodium oxybate. Behavioral measures including regular sleep schedules, planned naps, adequate nighttime sleep and avoidance of sleep deprivation are also important components of long-term management.

"Narcolepsy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Narcolepsy pipeline landscape is provided which includes the disease overview and Narcolepsy treatment guidelines. The assessment part of the report embraces, in depth Narcolepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Narcolepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Narcolepsy R&D. The therapies under development are focused on novel approaches to treat/improve Narcolepsy.

Narcolepsy Emerging Drugs Chapters

This segment of the Narcolepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Narcolepsy Emerging Drugs

Samelisant: Suven Life Sciences

Samelisant (SUVN-G3031) is an investigational, orally administered histamine H3 receptor inverse agonist developed by Suven Life Sciences for narcolepsy. By blocking/inversely activating H3 autoreceptors, it enhances histaminergic neurotransmission in the brain and is intended to promote wakefulness. The drug is currently being evaluated in a Phase III study in patients with narcolepsy, with excessive daytime sleepiness (EDS) as the primary efficacy endpoint and cataplexy frequency as an additional outcome. The program is designed to address both major manifestations of narcolepsy daytime sleepiness and cataplexy potentially providing a differentiated non-stimulant treatment approach.

E2086: Eisai Co Ltd

E2086 is an investigational, orally administered selective orexin-2 receptor (OX2R) agonist discovered and developed by Eisai for narcolepsy. It is designed to compensate for the loss of orexin signaling associated with narcolepsy, thereby promoting wakefulness and potentially reducing cataplexy. In a Phase Ib study in narcolepsy type 1, E2086 significantly increased wakefulness versus placebo and modafinil, providing proof of mechanism. The drug is being evaluated in a Phase II clinical trial in adults with narcolepsy to determine optimal doses and assess its ability to reduce excessive daytime sleepiness.

Further product details are provided in the report……..

Narcolepsy: Therapeutic Assessment

This segment of the report provides insights about the different Narcolepsy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Narcolepsy
• There are approx. 12+ key companies which are developing the therapies for Narcolepsy. The companies which have their Narcolepsy drug candidates in the most advanced stage, i.e. Phase III include, Suven Life Sciences.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Narcolepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Narcolepsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Narcolepsy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Narcolepsy drugs.

Narcolepsy Report Insights

• Narcolepsy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Narcolepsy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Narcolepsy drugs?
• How many Narcolepsy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Narcolepsy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Narcolepsy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Narcolepsy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Suven Life Sciences
• Eisai Co Ltd
• Takeda
• Vertex Pharmaceuticals
• CiRC Biosciences
• Harmony Biosciences
• NewCelX

Key Products

• Samelisant
• E2086
• TAK-360
• VX-433
• CBS-105
• Research Program